BCA
RETA

Berman Capital Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Berman Capital Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5K Buy
50
+20
+67% +$2.34K ﹤0.01% 1450
2021
Q2 		$3K Buy
30
+21
+233% +$2.37K ﹤0.01% 1536
2021
Q1 		$0 Buy
+9
New +$1.05K ﹤0.01% 1952
2020
Q4 		– Sell
-7
Closed – – 1874
2020
Q3 		$0 Hold
7
– – ﹤0.01% 1825
2020
Q2 		$1K Buy
+7
New +$1.06K ﹤0.01% 1547

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Berman Capital Advisors's RETA Position: Q3 2021 in Review

Berman Capital Advisors increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 67% in Q3 2021, buying an estimated $2.34K and bringing the position to 50 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Berman Capital Advisors first reported a position in RETA in Q2 2020 and has held it in 5 quarters since. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

  • Berman Capital Advisors held 50 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $5K as of Q3 2021.
  • Berman Capital Advisors bought 20 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $2.34K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1450 holding.
  • Berman Capital Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and has held it in 5 quarters since.
  • 181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.